Breast

Papers
(The H4-Index of Breast is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Current and future burden of breast cancer: Global statistics for 2020 and 20401062
Global guidelines for breast cancer screening: A systematic review102
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer91
Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review73
Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis70
Global challenges in breast cancer detection and treatment64
Epidemiology of male breast cancer59
Dissecting the biological heterogeneity of HER2-positive breast cancer55
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis51
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis47
Effects of the COVID-19 pandemic on breast cancer screening in Taiwan43
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer42
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer41
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data fr39
Breast cancer surgery with augmented reality38
Occult breast cancer: Where are we at?38
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)36
A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction36
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy36
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D34
“The emerging role of capivasertib in breast cancer”34
Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,532
Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis32
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis31
The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy31
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era31
Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis30
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer29
De-escalating axillary surgery in early-stage breast cancer29
Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – A systematic review and meta-analysis29
0.059113025665283